Published on 12 Feb 2024 on Insider Monkey via Yahoo Finance

Here’s Why Adaptive Biotechnologies Corporation (ADPT) Declined in Q4

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Focus Growth Strategy” fourth quarter 2023 investor letter. A copy of the same can be downloaded here. The market rebounded in the fourth quarter as the S&P 500 Index rose 11.69%. Aristotle Atlantic’s Focus Growth strategy returned 15.02% gross of fees (14.99% net of fees), in the quarter outperforming the Russell 1000 Growth Index’s 14.16% total return. The relative outperformance was due to both allocation effects and security selection. In addition, you can check the top 5 holdings of the fund to know its best picks in 2023.

Aristotle Atlantic Focus Growth Strategy featured stocks such as Adaptive Biotechnologies Corporation (NASDAQ:ADPT) in the fourth quarter 2023 investor letter. Headquartered in Seattle, Washington, Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is a commercial-stage company that develops an immune medicine platform. On February 12, 2024, Adaptive Biotechnologies Corporation (NASDAQ:ADPT) stock closed at $3.92 per share. One-month return of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) was -8.84%, and its shares lost 54.84% of their value over the last 52 weeks. Adaptive Biotechnologies Corporation (NASDAQ:ADPT) has a market capitalization of $567.51 million.

Aristotle Atlantic Focus Growth Strategy stated the following regarding Adaptive Biotechnologies Corporation (NASDAQ:ADPT) in its fourth quarter 2023 investor letter: